There are 2789 resources available
1151MO - Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial
Presenter: Marie Wislez
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1732MO - Pembrolizumab and nintedanib for patients with advanced mesothelioma
Presenter: François-Xavier Danlos
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA43 - GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)
Presenter: Yi-Long Wu
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1171MO - PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Presenter: Nicolas Girard
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Introduction by the chair
Presenter: Florence Joly
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
Yes
Presenter: Isabelle Ray-Coquard
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
No
Presenter: Antonio Jose Gonzalez Martin
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Florence Joly
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
Q&A
Presenter: Florence Joly
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
Full session recording
Presenter: Keith Kerr
Session: Janssen - Expanding horizons for the targeted management of EGFR-Positive NSCLC
Resources:
Webcast